OBJECTIVE—To better define the efficacy and safety of rimonabant, the first selective
cannabinoid type 1 (CB1) receptor antagonist, in a large population of overweight and …

ContextRimonabant, a selective cannabinoid-1 receptor blocker, may reduce body weight
and improve cardiometabolic risk factors in patients who are overweight or obese …

Rimonabant is a first selective blocker of the cannabinoid receptor type 1 (CB1) being
developed for the treatment of multiple cardiometabolic risk factors, including abdominal …

Background Rimonabant, a selective cannabinoid-1 receptor (CB1) blocker, has been
shown to reduce body weight and improve cardiovascular risk factors in obese patients. The …

Background Rimonabant, a selective cannabinoid type 1 receptor blocker, reduces
bodyweight and improves cardiovascular and metabolic risk factors in non-diabetic …

Aims Rimonabant, the first selective cannabinoid type 1 receptor blocker, has been shown to
produce weight loss and improvements in several cardiometabolic risk factors over 1 year …

Objective Rimonabant, the first selective cannabinoid type 1 (CB 1) receptor blocker, has
been shown to improve multiple cardiometabolic risk factors in overweight/obese patients …

What is known and objective: Rimonabant, a cannabinoid receptor blocker, has recently
been used in clinical practice for weight loss and weight maintenance. Our aim was to …

Purpose. The pharmacology, pharmacokinetics, clinical efficacy, safety, drug interactions,
and dosage and administration of rimonabant in the treatment of obesity and related …

Background In animal models, cannabinoid-1 receptor (CB 1) blockade produces a lean
phenotype, with resistance to diet-induced obesity and associated dyslipidaemia. We …